Introduction
The evasion of immunity is now recognised as a hallmark of cancer alongside well established characteristics, such as loss of growth control, resistance to apoptosis and the ability to invade and metastasise [1] . Cancer development is initiated by mutations in cellular oncogenes and tumour suppressor genes. The first cellular oncogenes to be discovered were those belonging to the RAS family and mutant RAS molecules are found in 20-25% of human cancers [2, 3] . RAS proteins are small GTP-binding proteins that couple growth factor receptors to intracellular signalling pathways [2, 3] . Mutations in codons 12, 13 and 61 are the commonest in human cancer and all generate constitutively active RAS molecules [3] . The RAS pathway is directly linked to several key features of malignant development, such as cell cycle progression and survival. In addition, RAS signalling regulates several features associated with invasiveness and the development of the tumour microenvironment, including tumour angiogenesis [2, 3] .
Cytotoxic lymphocytes, namely natural killer (NK) cells and cytotoxic T cells (CTL), play a key role in the elimination of tumour cells [4] . The activity of both of these cell types is regulated by target cell MHC class I molecules [5, 6] . The T cell receptor (TCR) complex on CTL can recognise tumour-associated antigens (TAA) presented by MHC class I molecules and this interaction delivers a potent activating signal to the cognate CTL. In contrast, NK cells are negatively regulated by MHC class I molecules via the interaction with inhibitory killer cell immunoglobulin-like receptors (KIRs). Thus, whilst reduction of MHC class I expression on tumours allows evasion of CTL, it favours NK cell activation, providing the host with a powerful immune surveillance system. In addition, malignant cells frequently express cell surface ligands of the NKG2D and DNAM-1 molecules found on both NK cells and CTL. In NK cells, these deliver signals that cause NK cell activation in the absence of inhibitory signalling from KIR molecules [6, 7] . Once activated by tumour cells, CTL and NK cells exocytose cytotoxic granules containing granzymes and perforin molecules, inducing apoptosis in the tumour. In addition, both NK cells and CTL produce interferon (IFN)-γ which enhances antigen presentation and favours the development of cell mediated immunity [8] [9] [10] [11] .
Tumours frequently downregulate the expression of MHC class I molecules from the cell surface, allowing them to evade CTL recognition [12] . This can occur as a result of mutations in genes encoding critical components of the antigen presentation machinery, such as β2-microglobulin (β2M) [13] . The β2M molecule is required for the stable expression of the MHC class I/peptide complex at the cell surface and hence β2M mutations allow irreversible evasion of CTL [14] . However, reduction in tumour cell MHC class I expression can also occur by a second, reversible pathway [12, 15] . In this case, reduced expression of antigen presentation pathway components restricts the flow of peptide loaded MHC class I molecules to the cell surface [15] . Expression of oncogenic RAS has previously been linked with the reduced expression of antigen presentation pathway components in mouse cells and in human tumour tissue [16] [17] [18] (and reviewed in [3] ). These components include the transporter of antigen processing (TAP) and the TAP-associated molecule, tapasin, which are required for efficient delivery of antigenic peptides into the endoplasmic reticulum (ER) [14] . This suggests that targeted inactivation of oncogenic RAS may restore expression of MHC class I molecules to the cell surface and help to boost T cell recognition. However, there are conflicting reports on the association between RAS mutations and antigen presentation in human tumours [18] [19] [20] , indicating that functional studies are required. We have analysed the role of mutant RAS oncogenes in regulating the expression of MHC class I molecules and in determining the recognition of RAS mutant tumours by cytotoxic lymphocytes. Our results reveal that oncogenic RAS inhibits the antigen processing pathway in human tumour cells and that these RAS-mediated effects are reversible. However, enhancing the antigen processing pathway by targeting oncogenic RAS in these tumour cells did not alter their susceptibility to NK cells or CTL in vitro.
Materials ands Methods

Culture of tumour cell lines
The inactivation of mutant KRAS in HCT116 (termed H Mu here) and in DLD-1 (D  Mu ) generating HKe3 (termed H WT ) and DKO4 (D WT ) respectively, has been previously described [21] . Mutant and wild-type cells were cultured in DMEM supplemented with 10% foetal calf serum (FCS). The HCT116, SW480 and HT-1080 cells stably transfected with the anti-RAS iDAb were previously generated [22, 23] ; these cells were cultured in DMEM+10% FCS supplemented with 1mg/ml G418, 1µg/ml puromycin and 0.3mg/ml hygromycin B to maintain transfected constructs. For induction of iDAb expression, medium was supplemented with 50µg/ml doxycycline for 48 hours prior to analysis by flow cytometry or immunoblotting.
Protein and mRNA analysis
The following antibodies were used for flow cytometry (antigen, clone-fluorochrome, [24] using Taqman probe/primer sets from Applied Biosystems/Life Technologies.
Preparation and functional analysis of NK cells and MART-1 specific T cells
Human NK cells were prepared from blood samples using indirect immunomagnetic separation, using a kit from Miltenyi Biotec, as previously described [24] . NK cell purity, as judged by either the CD56+CD3 neg or NKp46+ cell surface phenotype was routinely >90%. For IL-2 stimulation, NK cells were cultured for 5-7 days in 50 units/ml IL-2 (R&D systems). NK cell mediated killing of tumour cells and granule exocytosis assays were performed as we have described previously [24] [25] [26] , including after siRNA transfection of target cells [26, 27] . T cells restricted to the HLA-A2
restricted MART-1 epitope were generated in vitro and assayed as described [28] .
The tumour target cells were pulsed with 10ng/ml of either MART-1 peptide (ELAGIGILTV) or the control HER2/neu peptide (ILHNGAYSL) for 30 minutes prior to co-culture with the CTL. Discarded blood donations (from the Leeds NHS Blood and Transplant Service) were used as a source of HLA-A2+ lymphocytes.
Results
Mutant RAS decreases cell surface expression of MHC class I molecules
The [21] . Flow cytometry using a pan-reactive anti- Thus, mutant KRAS inhibits the antigen presentation pathway but the pathway remains intact, suggesting that it could be enhanced by therapeutic targeting of mutant RAS.
A RAS-targeting strategy increases MHC class I expression in tumour cells
We verified the role of mutant RAS in inhibition of MHC class I expression using a separate approach. The selective targeting of mutant RAS is a major goal of cancer therapy. Strategies have been developed that allow the selection of antibody-like fragments (termed intracellular domain antibodies or iDAbs) that possess antigenspecificity within the intracellular environment [29] . This approach was used to develop an iDAb that selectively binds to the active conformation of RAS [23, 30] .
Inducible expression of this iDAb is coupled to a reduction in RAS signalling and reduced tumourigenicity in vivo [22, 23] . We analysed the effect of inducing anti-RAS iDAb expression in three cell lines, the colorectal cell lines HCT116 and SW480
containing mutant KRAS (G13D and G12V respectively), and HT-1080, a fibrosarcoma cell line with a mutant NRAS (Q61K). Induction of the iDAb resulted in increased expression of cell surface MHC class I in all three cell lines (Fig. 2) . The iDAb open reading frame is linked to GFP via an internal ribosome entry site [23] ; more pronounced MHC class I expression was observed in the cells exhibiting higher levels of GFP expression (Fig. 2) . Importantly, these results confirmed the data obtained using the H Mu /H WT isogenic pair ( Fig. 1 ) and showed that inactivation of all three common RAS mutants restored cell surface MHC class I expression to these tumour cell lines. Collectively, these results suggest that therapeutic blockade of oncogenic RAS might alter the recognition of these targeted cells by cytotoxic lymphocytes.
Mutant RAS and recognition by CTL
We first investigated whether the oncogenic RAS-mediated inhibition of MHC class I expression affected antigen-specific recognition by CTL. Use of established human tumour cell lines has the disadvantage that it is not possible to obtain autologous T cells. However, the HCT116 cell line expresses the HLA-A2 molecule ( Figure 1A) and it is possible to use in vitro priming to generate CD8+ T cell populations from healthy HLA-A2+ donors that are reactive against the HLA-A2 restricted melanoma antigen, MART-1 (Fig. 3A) . We pulsed H 3C ). (Fig. 4D and E) .
Mutant RAS does not alter NK cell recognition
Expression of NK cell activation ligands in the presence of oncogenic RAS
NK cell activation is not solely determined by target cell MHC class I expression, but by the balance of signals delivered from inhibitory receptors (including the KIRs) and activating receptors such as NKG2D and DNAM-1 [6, 7] . The human NKG2D molecule binds to a series of cell surface ligands, comprising members of the cytomegalovirus UL16 binding protein (ULBP) family and MHC Class I polypeptide related sequence (MIC)A and MICB [32] . Two ligands of DNAM-1 have been identified, PVR and Nectin-2 [6, 7] . We analysed the expression of ULBP1, ULBP2, MICA/B, PVR and Nectin-2 in the HCT116 and DLD-1 derived isogenic pairs.
Amongst these molecules, only ULBP2 showed consistent alteration in expression in the two backgrounds, with cell surface expression being reduced in the presence of oncogenic RAS (Fig. 5) . Furthermore, this reduction in ULBP2 expression in the presence of oncogenic RAS was mirrored at the mRNA level (data not shown). These results, together with those in Figure 1 , indicated that mutant KRAS reduces the cell surface expression of molecules that inhibit NK cells (MHC class I) as well as those that activate (ULBP2). However, this modulation did not affect the activation of NK cells or their ability to kill these tumour targets. [33, 34] . These findings prompted a series of studies investigating the ability of different oncogenes to modulate MHC class I expression [35] [36] [37] [38] . Subsequently, oncogenic RAS was shown to reduce cell surface expression of mouse MHC class I molecules [16, 17] and this was associated with reduced CTL recognition [17] . The reduced expression of MHC class I molecules in human tumours is well documented [12] . Early immunohistochemical studies showed that there were three phenotypes of colorectal cancer; absence of MHC class I expression was observed in approximately one third of samples, whereas two-thirds of samples had reduced MHC class I expression. Tumours with apparently normal levels of MHC class I expression were a very small minority, accounting for less than one in twenty cases [39] . RAS mutations have been associated with reduced expression of antigen processing pathway components in human tumour samples [18] , although earlier studies did not reach this conclusion [19, 20] HLA-A2 by less than two-fold and this difference did not significantly alter T cell recognition. However, the use of exogenous antigenic peptide in our assays may underestimate the effect of oncogenic RAS inhibition on antigen-specific CTL recognition since the inhibition of peptide transport into the ER will be negated. HLA-C1 and HLA-C2 epitopes (HLA-Cw7 and Cw5 respectively) and will thus engage KIR2DL1, 2DL2 and 2DL3, which are common amongst KIR haplotypes [43, 44] . Similar to the situation with CTL, it is likely that the relatively small inhibition in cell surface MHC class I expression is insufficient to alter NK cell recognition. The existence of a threshold of NK cell activation/inhibition regulated by MHC class I levels [26, 45, 46] In colorectal cancer, patients whose tumours expressed high levels of MHC class I showed similar survival times to those whose tumours had lost MHC class I [47] . However, patients with reduced MHC class I expression had the worst prognosis of these three groups; the authors of this study suggest that reduced MHC class I levels on these tumours might be insufficient to mediate CTL recognition but are nevertheless still capable of inhibiting NK cell activity, rendering the tumour resistant to both classes of cytotoxic lymphocytes [47] . By inhibiting expression of multiple antigen presentation pathway components, mutant RAS molecules reduce total MHC class I expresssion levels at the cell surface. Expression of the major inhibitory ligands of NK cells, HLA-B and -C, is highly dependent upon TAP, tapasin and β2M, all of which are downregulated by oncogenic RAS. Further investigation is required to determine the effects of oncogenic RAS on individual HLA molecules and how these might alter tumour cell recognition by both NK cells and CTL. Indeed, the differential regulation of HLA molecules is exploited by HIV, allowing infected cells to minimise their recognition by both CTL and NK cells [48] and, in melanoma, HLA expression patterns are believed to be shaped by immune selection [49] .
Discussion
The mechanisms that underlie the expression of NKG2D ligands are beginning to be uncovered [50] . Oncogenic transformation itself is insufficient to induce NKG2D ligand expression [51] . However, a variety of stress signals (such as DNA damage and intracellular infection) result in expression of these ligands [32, 51, 52] . The existence of multiple NKG2D ligands presumably allows coupling of different stress signals to the expression of different ligands, providing the host with an efficient response system to eliminate damaged cells [32, 52] . Oncogenic RAS inhibited the expression of the NKG2D ligand ULBP2 in both the HCT116 and DLD1
backgrounds, yet in neither case did this alter their susceptibility to NK cells. This is most likely because NK cells express a large repertoire of activating and inhibitory receptors whose signals intersect to control activation [6, 7] . Either the change in [22] . Hence, the concept of oncogene addiction does not apply in this instance [61] . This suggests that agents targeting RAS will need to be combined with other strategies for effective therapy. Direct inhibition of RAS activity has not met with great success [62] , but targeting of downstream signalling molecules (such as RAF and MEK) holds promise [63] . In addition, synthetic lethality screens have identified potential targets selective to RAS mutant cells [64] . We did not find statistically significant differences in the CTL recognition of H Mu and H WT cells.
However 
